How to use Vebreltinib, dosage reference

Vebreltinib is a new type of targeted drug that belongs to the MET inhibitor category. It is mainly used to treat non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation (METex14 skipping mutation) and some patients with glioma. It blocks the growth signaling of tumor cells and inhibits tumor cell proliferation and metastasis by selectively inhibiting the activity of MET receptor tyrosine kinase. The drug is one of the important breakthroughs in the field of precision medicine in recent years, especially in patients who have shown significant potential efficacy in patients who have failed to respond to other treatments.

In terms of usage and dosage, the recommended dosage of bricitinib varies according to different indications. For patients with non-small cell lung cancer, the recommended starting dose is 200 mg orally twice daily (morning and evening). For patients with glioma, the starting dose can be appropriately increased to 300mg, taken orally twice a day (once in the morning and once in the evening). This dose difference is mainly due to differences in the pharmacokinetic characteristics of central nervous system tumors and the ability of drugs to penetrate the blood-brain barrier.

In terms of taking the medicine, it is recommended to take britinib on an empty stomach, that is, fasting at least 2 hours before taking the medicine and half an hour after taking the medicine, but you can drink an appropriate amount of water. Taking it on an empty stomach can help improve the bioavailability of the drug and prevent food from interfering with the absorption rate. If the patient experiences indigestion, mild nausea or discomfort while taking the medication, the medication time can be adjusted or combined with light food under the guidance of a doctor.

The treatment cycle of bricitinib is usually continued until the disease progresses or the patient cannot tolerate it. During the treatment process, the doctor may make individual adjustments to the dose based on the patient's tolerance, blood indicators and adverse drug reactions. Some patients may need to reduce the dose during long-term use to reduce toxic reactions. For example, if liver function abnormalities or fatigue occur, the dose may be reduced to 150 mg twice a day or the medication may be suspended.

Reference materials:https://www.asymbio.com.cn/